Efficacy and safety of basiliximab in kidney transplantation

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 473-490

  Boggi, Ugo ^a   Vistoli, Fabio ^a   Signori, Stefano ^a   Del Chiaro, Marco ^a   Amorese, Gabriella ^b   Barsotti, Massimiliano ^b   Rizzo, Gaetano ^b   Marchetti, Piero ^a   Danesi, Romano ^a   Del Tacca, Mario ^a   Mosca, Franco ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Dept of Clin Microbiol Lab   (Italy)

Author keywords

Basiliximab; Benefit; Renal transplantation; Risk

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANAPHYLAXIS; AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MICROEMULSION; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PEDIATRICS; PNEUMOCYSTIS PNEUMONIA; RECIPIENT; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; T CELL DEPLETION; TREATMENT FAILURE; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; RISK FACTORS; T-LYMPHOCYTES;

EID: 21144438720     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.473     Document Type: Review

References (86)

1. MURRAY JE, MERILL JP, HARRISON JH: Kidney transplantation between seven pairs of identical twins. Ann. Surg. (1958) 148(3):343-359.
2. DANESI R, MOSCA M, BOGGI U, MOSCA F, DEL TACCA M: Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol. Med. Today (2000) 6(12):475-482.
3. KAHAN BD, PONTICELLI C, (Eds): Principles and practice of renal transplantation. Martin Dunitz Ltd, London: (2000).
4. GLOOR J. Kidney transplantation in the hyperimmunized patient. In: Kidney transplantation: strategies to prevent organ rejection. Ronco C, Chiaramonte S, Remuzzi G (Eds), Karger, Basel (Switzerland) (2005) 11-21.
5. CECKA JM: The UNOS scientific renal transplant registry. In: Clinical transplants 1998. Terasaki PI, Cecka JM, (Eds), UCLA Tissue Typing Laboratory, Los Angeles (CA) (1999) 421-436.
6. BIRKELAND SA: Uremia as a state of immune deficiency. Scand J. Immunol. (1976) 5(1-2):107-115.
7. DESCAMPS-LATSCHA B, HERBELIN A, NGUYEN AT, ZINGRAFF J, JUGERS P, CHATENOUD L: Immune system dysregulation in uremia. Semin. Nephrol. (1994) 14(3):253-260.
8. EHRICH JH, LOIRAT C, BRUNNER FP et al.: Report on management of renal failure in children in Europe, XXII, 1991. Nephrol. Dial. Transplant. (1992) 7(Suppl. 2):36-48
9. FEUCHT HE, OPELZ G: The humoral immune response towards HLA class II determinants in renal transplantation. Kidney (1996) 50(5):1464-1475
10. CARMELLINI M, VISTOLI F, BOGGI U, BELLINI R, MOSCA F: Delayed graft function incidence as predictive variable of survival of kidney grafts retrieved from elderly donors. Transplant. Proc. (2000) 32(1):128-130
11. GRINYO' JM, CRUZADO JM: Steroid or calcineurin inhibitor-sparing Immunosuppressive protocols. In: Kidney transplantation. strategies to prevent organ rejection. Ronco C, Chiaramonte S, Remuzzi G (Eds.). Karger, Basel (2005) 31-42.
12. BOGGI U, DANESI R, VISTOLI F et al.: A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf. (2004) 27(2):91-106.
13. CHAPMAN TM, KEATING GM: Basiliximab A review of its use as induction therapy in renal transplantation. Drugs (2003) 63(24):2803-2835.
14. MORRIS JC, WALDMANN TA: Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. (2000) 59(Suppl. 1):109-114.
15. GAFFEN SL: Signaling domains of the interleukin 2 receptor. Cytokine (2001) 14(2):63-77.
16. ELLERY JM, NICHOLLS PJ: Possible mechanism for the alpha-subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction. Immunol. Cell Biol. (2002) 80(4):351-357.
17. GOEBEL J, STEVENS E, FORREST K, ROSZMAN TL, IJZERMANS JM, WEIMAR W: Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol. (2000) 8(3):153-159.
18. BAAN CC, VAN RIEMSDIJK-OVERBEEKE IC, BOELAARS-VAN HAPEREN MJ et al.: Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl. Immunol. (2002) 10(1):81-87.
19. KOVARIK JM, KAHAN BD, RAJAGOPALAN PR et al.: Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The United States Simulect Renal Transplant Study Group. Transplantation (1999) 68(9):1288-1294.
20. MENTRE F, KOVARIK J, GERBEAU C: Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. J. Pharmacokinet. Biopharm. (1999) 27(2):213-230.
21. KOVARIK J, WOLF P, CISTERNE JM et al.: Dis position of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation (1997) 64(12):1701-1705.
22. KOVARIK JM, MOORE R, WOLF P et al.: Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin. Transplant. (1999) 13(1 Pt 1):32-38.
23. KOVARIK JM, PESCOVITZ MD, SOLLINGER HW et al.: Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. The Simulect Phase IV Study Group. Clin. Transplant. (2001) 15(2): 123-130.
24. KOVARIK JM, NASHAN B, NEUHAUS P et al.: A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin. Pharmacol. Ther. (2001) 69(4):201-209.
25. KOVARIK JM, OFFNER G, BROYER M et al.: A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation (2002) 74(7):966-971.
26. STREHLAU J, PAPE L, OFFNER G et al.: Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet (2000) 356(9238):1327-1328.
27. NASHAN B, MOORE R, AMOLT P et al.: Randomised trial basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 350(9086):1193-1198.
28. KAHAN BD, RAJAGOPALAN PR, HALL M: Reduction of occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric antiterleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 67(2):276-284.
29. KOVARIK JM, KORN A, CHODOFF L: Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients. Transplant. Proc. (2001) 33(7-8):3172-3173.
30. SIFONTIS N, BENEDETTI E, VASQUEZ E: Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant. Proc. (2002) 34(5):1730-1732.
31. BAUDOUIN V, CRUSIAUX A, HADDAD E et al.: Anaphylactic shock caused by immunoglobulin e sensitization after retreatment with chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation (2003) 76(3):459-463.
32. BARROS VR, ROCHA V, GARCIA VD, GARCIA CD: Anaphylactic shock after retreatment with basiliximab, Transplant. Proc. (2003) 35(1):579.
33. SHAH MH, BOKHARI MZ, BOKHARI MT, FAROOQ A, YOUSAF SM: Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients. Transplant. Proc. (2003) 35(7):2737-2738.
34. PONTICELLI C, YUSSIM A, CAMBI V et al.: A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Simulect Phase IV Study Group. Transplantation (2001) 72(7):1261-1267.
35. FOLKMANE I, BICANS J, AMERIKA D, CHAPENKO S, MUROVSKA M, ROSENTALS R: Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab. Transplant. Proc. (2001) 33(7-8):3209-3210.
36. BOGGI U, VISTOLI F, DEL CHIARO M, BARTOLO TV, RIZZO G, MOSCA F: CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab cadaveric kidney transplantation. Transplant. Proc. (2001) 33(7-8):3199-3200.
37. SIWACH V, DHANDA R, AGGARWAL B, SINGH B, JAIN PK, SARIN PK: Early experience with Simulect (basiliximab) induction in living donor renal allografting in India. Transplant. Proc. (2003) 35(I):196-197.
38. LAWEN JG, DAVIES EA, MOURAD G ET AL.: Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Simulect International Study Group. Transplantation (2003); 75(1):37-43.
39. SOLLINGER H, KAPLAN B, PECOVITZ MD et al.: Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation (2001) 72(12):1915-1919.
40. LEBRANCHU Y, BRIDOUX F, BÜCHLER M et al.: Immunoprophylaxis with basiliximab compared with antithymocyte globulin renal transplant patients receiving MMF-containing i triple therapy. Am. J. Transplant. (2002) 2(1):48-56.
41. VINCENTI F, MONACO A, GRINYO J, KINKHABWALA M, ROZA A: Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am. J. Transplant. (2003) 3(3):306-311.
42. KODE R, FA K, CHOWDHURY S et al.: Basiliximab plus low-dose cyclosporin versus OKT3 for induction immunosuppression following renal transplantation. Clin. Transplant. (2003) 17(4):369-376.
43. BALBONTIN F, KIBERD B, SINGH D et al.: Basiliximab widens the therapeutic window for AUC-monitored Neoral therapy early after kidney transplantation. Transplant. Proc. (2003) 35(7):2409-2411.
44. KUNG SC, PARIKH M, FYFE B et al.: Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients. Transplant. Proc. (2004) 36(Suppl. 2S):475S-477S.
45. KIBERD BA, LAWEN J, FRASER AD, KEOUGH-RYAN T, BELITSKY P: Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am. J. Transplant. (2004) 4(7): 1079-1083.
46. VITKO S, TEDESCO H, ERIS J et al.: Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am. J. Transplant. (2004) 4(4):626-635.
47. MARTIN GARCIA D, MARTIN GAGO J, MENDILUCE A, GORDILLO R, BUSTAMENTE J: Tacrolimus-basiliximab versus cyclosporine-basiliximab in renal transplantation 'de novo': acute rejection and complications. Transplant. Proc. (2003) 35(5):1694-1696.
48. LEONARDI G, MESSINA M, GIRAUDI R, PELLU V, FOP F, SEGOLONI GP: Basiliximab in association with tacrolimus and steroids in caucasian cadaveric renal transplanted patients: significant decrease in early acute rejection rate and hospitalization time. Clin. Transplant. (2004) 18(2): 113-118.
49. TULLIUS SG, PRATSCHKE J, STROBELT V et al.: ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant. Proc. (2003) 35(6):2100-2101.
50. WILAND AM, FINK JC, WEIR MR et al.: Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation (2004) 77(3):422-425.
51. RAHAMIMOV R, YUSSIM A, AFTER T et al.: Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol. Transplant. Proc. (2003) 35(2):653-654.
52. THISTLETHWAITE JR JR, NASHAN B, HALL M, CHODOFF L, LIN TH: Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. Transplantation (2000) 70(5):784-790.
53. BOGGI U, VISTOLI F, COPPELLI A, MARCHETTI P, RIZZO G, MOSCA F: Use of basiliximab in conjunction with either Neoral/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. Transplant. Proc. (2001) 33(7-8):3201-3202.
54. CHOW FY, POLKINGHORNE K, SAUNDER A, KERR PG, ATKINS RC, CHADBAN SJ: Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrology (Carlton) (2003) 8(4):212-216.
55. KUMAR MS, KODE RK, PANKEWYCZ et al.: Simulect, Neoral, Cellcept and prednisone in kidney recipients with delayed graft function: a prospective controlled study. Transplant. Proc. (2001) 33(7-8):3762-3763.
56. VESTER U, KRANZ B, TESTA G et al.: Efficacy and tolerability interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr. Transplant. (2001) 5(4):297-301
57. PAPE I, STREHLAU J, HENNE T et al.: Single centre experience with basiliximab in paediatric renal transplantation. Nephrol. Dial. Transplant. (2002) 17(2):276-280.
58. CLARK G, WALSH G, DESHPANDE P, KOFFMAN G: Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol. Dial. Transplant. (2002) 17(7):1304-1309.
59. VESTER U, KRANZ B, TESTA G, PAUL A BROELSCH CE, HOYER PF: Medical and Surgical Aspects of Pediatric Renal Transplantation Using Living Donors. Transplant. Proc. (2004) 36(5):1308-1310.
60. GARCÍA MESEGUER C, VILA LÓPEZ A, LUQUE DE PABLOS A, VALLO BOADO A, SIMON JM: Immunoprophylaxis with Simulect (Basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units. The Pediatric EOSS Study Group. Transplant. Proc. (2003) 35(5):1697-1698.
61. DUZOVA A, BUYAN N, BAKKALOGLU M et al.: Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant. Proc. (2003) 35(8):2878-2880.
62. HEISEL O, HEISEL R, BALSHAW R, KEOWN P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am. J. Transplant. (2004) 4(4):583-595.
63. DE MATTOS AM, OLYAEI AJ, BENNETT WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am. J. Kidney Dis. (2000) 35(2):333-346.
64. FLECHNER SM, GOLDFARB D, MODLIN C et al.: Kidney transplantation without calcineurin inhibitor drugs: a prospective randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 74(8):1070-1076.
65. PISANI F, BUONUOMO O, IARIA G et al.: Sirolimus in kidney transplantation from marginal donors. Transplant. Proc. (2004) 36(3):495-496.
66. BAMGBOLA FO, DEL RIO M, KASKEL FJ, FLYNN JT. Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients. Pediatr. Transplant. (2003) 7(4):315-320.
67. LO A, STRATTA RJ, ALLOWAY RR et al.: Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl. Int. (2001) 14(6):396-404.
68. SWIATECKA-URBAN A, GARCIA C, FEUERSTEIN D et al.: Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr. Nephrol. (2001) 16(9):693-696
69. CHERIKH WS, KAUFFMAN HM, MCBRIDE MA, MAGHIRANG J, SWINNEN LJ, HANTO DW: Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation (2003) 76 (9): 1289-1293
70. ABRAMOWICZ D, CRUSIAUX A, GOLDMAN M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N. Engl. J. Med. (1992) 327(10):736.
71. LEONARD PA, WOODSIDE KJ, GUGLIUZZA KK, SUR S, DALLER JA: Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation (2002) 74(12):1697-1700.
72. ADU D, COCKWELL P, IVES NJ, SHAW J, WHEATLEY K: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. Br. Med. J. (2003) 326 (7393):789.
73. WEBSTER AC, PLAYFORD EG, HIGGINS G, CHAPMAN JR, CRAIG JC: Interleukin 2 receptor anatgonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 77(2):166-176.
74. KEOWN PA, BALSHAW R, KRUEGER H, BALADI JF: Economic analysis of basiliximab in renal transplantation. Transplantation (2001) 71(11):1573-1579.
75. LORBERMI, FASTENAU J, WILSON D, DI CESARE J, HALL ML: A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin. Transplant. (2000) 14(5):479-485.
76. POLSKY D, WEINFURT KP, KAPLAN B, KIM J, FASTENAU J, SCHULMAN KA: An economic and quality-of-life assessment of basiliximab versus antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol. Dial. Transplant. (2001) 16(5):1028-1033.
77. LILLIU H, BRUN-STRANG C, LE PEN C et al.: Cost-minimization study comparing Simulect® versus Thymoglobulin® in renal transplant induction. Clin. Transplant. (2004) 18(3):247-253.
78. AALAMIAN Z. Reducing adverse events of immunosuppressive agents in kidney transplanta recipients. Prog. Transplant. (2001); 11(4):271-282.
79. European Renal Association and European Dialysis and Transplant Association. Section III: the transplant recipient from initial transplant hospitalization to 1 year post transplant. Nephrol. Dial. Transplant. (2000); 15(Suppl. 7):52-85.
80. BUSH WW. Overview of transplantation immunology and pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression. Transplantation (1999) 10(2):253-269.
81. WILDE MI. GOA KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs (1996) 51(5):865-894.
82. AMLOT PL, RAWLINGS E, FERNANDO ON et al. Prolonged action of a chimeric interleukin-2-receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation (1995) 60(7):748-756.
83. STERKERS G, BAUDOUIN V, ANSART-PIRENNE H et al. Duration of action of a chimeric interleukin-2 recpetor monoclonal antibody; basiliximab, in pediatric kidney transplant recipients. Transplant. Proc. (2000) 32(8):2757-2759.
84. LINDHOLM A, OHLMAN S, ALBRECHTSEN D, TUFVESON G, PERSSON H, PERSSON NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplant recipients threated by 3 cyclosporine regimens. Transplantation (1993) 56(2):307-315.
85. MATAS AJ, GILLINGHAM KJ, PAYNE WD, NAJARIAN JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation (1994) 57(6):857-859
86. BASADONNA GP, MATAS AJ, GILLINGHAM KJ et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation (1993) 55(5):993-995.